As of July 2025, Asian markets are navigating a complex landscape marked by mixed economic signals and geopolitical developments. While China's growth has eased pressure for immediate stimulus, concerns about deflation and property market weakness linger, influencing investor sentiment across the region. In such an environment, companies with high insider ownership often attract attention as they may signal confidence from those closest to the business.
Top 10 Growth Companies With High Insider Ownership In Asia
| Name | Insider Ownership | Earnings Growth |
| Zhejiang Leapmotor Technology (SEHK:9863) | 15.6% | 61% |
| Vuno (KOSDAQ:A338220) | 15.6% | 109.8% |
| Suzhou Sunmun Technology (SZSE:300522) | 35.4% | 77.7% |
| Shanghai Huace Navigation Technology (SZSE:300627) | 24.3% | 23.5% |
| Oscotec (KOSDAQ:A039200) | 12.7% | 98.7% |
| Novoray (SHSE:688300) | 23.6% | 28.2% |
| M31 Technology (TPEX:6643) | 30.8% | 63.4% |
| Laopu Gold (SEHK:6181) | 35.5% | 42.6% |
| Gold Circuit Electronics (TWSE:2368) | 31.4% | 25.9% |
| Fulin Precision (SZSE:300432) | 13.6% | 43.7% |
Below we spotlight a couple of our favorites from our exclusive screener.
Ascentage Pharma Group International (SEHK:6855)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing therapies for cancers, chronic hepatitis B virus, and age-related diseases in Mainland China, with a market cap of HK$26.61 billion.
Operations: The company's revenue segment includes the development and sale of novel small-scale therapies, generating CN¥980.65 million.
Insider Ownership: 13.5%
Earnings Growth Forecast: 62.9% p.a.
Ascentage Pharma Group International, a growth-focused company in Asia with substantial insider ownership, recently completed a HK$1.51 billion equity offering to support its expansion. The company has achieved significant milestones with the approval of lisaftoclax for CLL/SLL treatment in China and ongoing global Phase III trials. Despite being currently unprofitable, Ascentage is projected to see revenue grow 23.2% annually and become profitable within three years, driven by innovative drug developments like lisaftoclax and olverembatinib.
- Get an in-depth perspective on Ascentage Pharma Group International's performance by reading our analyst estimates report here.
- Our expertly prepared valuation report Ascentage Pharma Group International implies its share price may be too high.
Shanghai Putailai New Energy TechnologyLtd (SHSE:603659)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Shanghai Putailai New Energy Technology Co., Ltd. develops and sells lithium-ion battery materials and automation equipment in China, with a market cap of CN¥38.81 billion.
Operations: The company generates revenue from the development and sale of materials for lithium-ion batteries and automation equipment within China.
Insider Ownership: 37%
Earnings Growth Forecast: 28.9% p.a.
Shanghai Putailai New Energy Technology Ltd. is experiencing robust earnings growth, forecasted at 28.9% annually, outpacing the Chinese market average of 23.4%. Despite recent removal from major indices like SSE 180, it trades below estimated fair value and shows strong relative value against peers. Revenue growth is projected at a slower pace of 15.4%, yet still above the market's average. The company maintains an unstable dividend track record but recently announced a CNY 0.17 per share dividend payout.
- Dive into the specifics of Shanghai Putailai New Energy TechnologyLtd here with our thorough growth forecast report.
- Our comprehensive valuation report raises the possibility that Shanghai Putailai New Energy TechnologyLtd is priced lower than what may be justified by its financials.
SICC (SHSE:688234)
Simply Wall St Growth Rating: ★★★★★☆
Overview: SICC Co., Ltd. is involved in the research, development, production, and sale of silicon carbide semiconductor materials both in China and internationally, with a market cap of CN¥25.38 billion.
Operations: The company's revenue primarily comes from its semiconductor material segment, which generated CN¥1.75 billion.
Insider Ownership: 30.2%
Earnings Growth Forecast: 35.6% p.a.
SICC Co., Ltd. is experiencing substantial growth, with earnings expected to rise significantly at 35.6% annually, surpassing the Chinese market's average growth rate of 23.4%. Revenue is projected to grow at a robust 21.4% per year, well above the market's 12.5%. Despite a recent decline in net income and revenue compared to last year, insider ownership remains high, reflecting strong internal confidence in future prospects amid strategic financial maneuvers approved by shareholders.
- Take a closer look at SICC's potential here in our earnings growth report.
- Upon reviewing our latest valuation report, SICC's share price might be too optimistic.
Key Takeaways
- Embark on your investment journey to our 589 Fast Growing Asian Companies With High Insider Ownership selection here.
- Ready For A Different Approach? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if SICC might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com